Startup profile · funding coverage
Phlotonics funding, valuation and investors
Silicon photonic biosensors for real-time monitoring in biomanufacturing and drug discovery.
Keep track of Phlotonics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Rochester, NY
Overview
Phlotonics develops scalable silicon photonic biosensors that measure secreted proteins and small molecules in real time for biomanufacturing, drug discovery, and regenerative medicine. Headquartered at 260 E. Main St., Rochester, NY, the company emerged from University of Rochester / RIT / AIM Photonics collaborations.
Why Phlotonics is interesting
Rochester photonics × biotech: label-free multiplexed photonic sensors aimed at PAT and regenerative-medicine manufacturing — Luminate/NextCorps-class commercialization story with BARDA-linked research ties.
Product & use cases
Compact multiplexed photonic biosensing platform for continuous, label-free biomolecular monitoring.
- Inline bioprocess analytics (PAT)
- Drug discovery tissue-model monitoring
- Cell therapy manufacturing QC
Key facts
- Rochester HQ — silicon photonic biosensors
- Use cases: biomanufacturing PAT, drug discovery, cell therapy manufacturing
- BARDA-linked subcontract work reported via NextCorps/UR collaborations
Competitive landscape
Edge: Silicon photonics multiplex sensing designed for scalable biomanufacturing workflows.
-
Conventional ELISA / offline assays incumbent
Batch lab assays vs continuous photonic monitoring.
-
Other photonic/SPR biosensor vendors direct
Label-free optical biosensing platforms.
Industries
FAQs about Phlotonics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.